Joel R Hecht
|
Title(s) | Professor of Clinical , Medicine |
---|
School | Medicine |
---|
Address | 760 Westwood Plaza 32-144 Los Angeles CA 90024
|
---|
Phone | (310) 829-5471 |
---|
vCard | Download vCard |
---|
|
|
ORNG Applications Bibliographic
Altmetrics Details
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media.
(Note that publications are often cited in additional ways that are not shown here.)
Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication.
Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.)
Click a Field or Translation tag to filter the publications.
-
CAUTION ADVISED USING COMBINATION KETOCONAZOLE AND PD-1 INHIBITORS. AACE Clin Case Rep. 2020 Sep-Oct; 6(5):e239-e242.
Yang Y, Hecht JR, Liu ST, Cohen MJ, Hart SD, Wang HL, Heaney AP. PMID: 32984529.
View in: PubMed Mentions:
-
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs. 2021 Feb; 39(1):182-192.
Hecht JR, Papadopoulos KP, Falchook GS, Patel MR, Infante JR, Aljumaily R, Wong DJ, Autio KA, Wainberg ZA, Bauer TM, Javle M, Pant S, Bendell J, Hung A, Ratti N, VanVlasselaer P, Verma R, Leveque J, Rao S, Oft M, Naing A. PMID: 32910338.
View in: PubMed Mentions: Fields:
-
Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Immunotherapy. 2019 06; 11(8):705-723.
Raman SS, Hecht JR, Chan E. PMID: 31045464.
View in: PubMed Mentions: 9 Fields: Translation: HumansCells
-
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project. J Natl Cancer Inst. 2018 06 01; 110(6):638-648.
Sjoquist KM, Renfro LA, Simes RJ, Tebbutt NC, Clarke S, Seymour MT, Adams R, Maughan TS, Saltz L, Goldberg RM, Schmoll HJ, Van Cutsem E, Douillard JY, Hoff PM, Hecht JR, Tournigand C, Punt CJA, Koopman M, Hurwitz H, Heinemann V, Falcone A, Porschen R, Fuchs C, Diaz-Rubio E, Aranda E, Bokemeyer C, Souglakos I, Kabbinavar FF, Chibaudel B, Meyers JP, Sargent DJ, de Gramont A, Zalcberg JR. PMID: 29267900.
View in: PubMed Mentions: 23 Fields: Translation: HumansCTClinical Trials
-
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma. Oncologist. 2017 03; 22(3):243-e23.
Hecht JR, Benson AB, Vyushkov D, Yang Y, Bendell J, Verma U. PMID: 28246207.
View in: PubMed Mentions: 15 Fields: Translation: HumansCTClinical Trials
-
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2016 Feb 10; 34(5):443-51.
Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero A, Salman P, Li J, Protsenko SA, Wainberg ZA, Buyse M, Afenjar K, Houé V, Garcia A, Kaneko T, Huang Y, Khan-Wasti S, Santillana S, Press MF, Slamon D. PMID: 26628478.
View in: PubMed Mentions: 147 Fields: Translation: HumansCTClinical Trials
-
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol. 2015 Dec 01; 33(34):4032-8.
Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. PMID: 26460303.
View in: PubMed Mentions: 144 Fields: Translation: HumansCTClinical Trials
-
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat Rev. 2015 Sep; 41(8):653-9.
Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R. PMID: 26220150.
View in: PubMed Mentions: 17 Fields: Translation: Humans
-
Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer. Anticancer Res. 2015 Mar; 35(3):1567-73.
Hecht JR, Reid TR, Garrett CR, Beck JT, Davidson SJ, Mackenzie MJ, Brandt U, Rizvi S, Sharma S. PMID: 25750312.
View in: PubMed Mentions: 2 Fields: Translation: HumansCTClinical Trials
-
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2015 Jun; 14(2):72-80.
Hecht JR, Cohn A, Dakhil S, Saleh M, Piperdi B, Cline-Burkhardt M, Tian Y, Go WY. PMID: 25982297.
View in: PubMed Mentions: 29 Fields: Translation: HumansCTClinical Trials
-
Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. J Clin Oncol. 2015 Jan 01; 33(1):22-8.
Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ. PMID: 25385741.
View in: PubMed Mentions: 25 Fields: Translation: Humans
-
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol. 2011 May 20; 29(15):1997-2003.
Hecht JR, Trarbach T, Hainsworth JD, Major P, Jäger E, Wolff RA, Lloyd-Salvant K, Bodoky G, Pendergrass K, Berg W, Chen BL, Jalava T, Meinhardt G, Laurent D, Lebwohl D, Kerr D. PMID: 21464406.
View in: PubMed Mentions: 59 Fields: Translation: HumansCTClinical Trials
-
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol. 2010 Sep 20; 28(27):4240-6.
Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, Hollywood E, Shia J, Schwartz J, Chandrawansa K, Dontabhaktuni A, Youssoufian H, Solit DB, Saltz LB. PMID: 20713879.
View in: PubMed Mentions: 55 Fields: Translation: HumansCellsCTClinical Trials
-
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer. 2010 Apr; 9(2):95-101.
Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I. PMID: 20378503.
View in: PubMed Mentions: 16 Fields: Translation: HumansCTClinical Trials
-
Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res. 2010 Apr 01; 16(7):2205-13.
Hecht JR, Mitchell E, Neubauer MA, Burris HA, Swanson P, Lopez T, Buchanan G, Reiner M, Gansert J, Berlin J. PMID: 20332321.
View in: PubMed Mentions: 35 Fields: Translation: HumansCTClinical Trials
-
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10; 27(5):672-80.
Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. PMID: 19114685.
View in: PubMed Mentions: 246 Fields: Translation: HumansCTClinical Trials
-
Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice. Am J Health Syst Pharm. 2008 Jun 01; 65(11 Suppl 4):S15-21; quiz S22-4.
Hecht JR. PMID: 18499885.
View in: PubMed Mentions: 2 Fields: Translation: Humans
-
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20; 25(15):1960-6.
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. PMID: 17452677.
View in: PubMed Mentions: 1214 Fields: Translation: HumansCTClinical Trials
-
Successful gastrointestinal cancer drug development. Semin Oncol. 2006 Dec; 33(6 Suppl 11):S24-7.
Hecht JR. PMID: 17178281.
View in: PubMed Mentions: Fields: Translation: Humans
-
Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med. 2005 Apr; 46(4):587-95.
Kim JH, Czernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, Ratib O, Phelps ME, Weber WA. PMID: 15809480.
View in: PubMed Mentions: 16 Fields: Translation: Humans
-
Improved imaging and the clinician: the role of positron emission tomography in the management of colorectal cancer. Mol Imaging Biol. 2004 Jul-Aug; 6(4):208-13.
Hecht JR. PMID: 15262236.
View in: PubMed Mentions: 3 Fields: Translation: Humans
-
Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia. Oncology (Williston Park). 2003 Sep; 17(9 Suppl 8):13-5.
Hecht JR, Blanke CD, Benson AB, Lenz HJ. PMID: 14569841.
View in: PubMed Mentions: 3 Fields: Translation: Humans
-
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res. 2003 Feb; 9(2):555-61.
Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM. PMID: 12576418.
View in: PubMed Mentions: 135 Fields: Translation: HumansCellsCTClinical Trials
-
Adjuvant therapy for gastric cancer: a reality at last. Curr Gastroenterol Rep. 2000 Dec; 2(6):478-81.
Hecht JR. PMID: 11079050.
View in: PubMed Mentions: Fields: Translation: Humans
This graph shows the total number of publications by year. To see the data as text, click here.
This graph shows the total number of publications by year. To return to the graph, click here.
Year | Publications |
---|
2000 | 1 | 2003 | 2 | 2004 | 1 | 2005 | 1 | 2006 | 1 | 2007 | 1 | 2008 | 2 | 2010 | 3 | 2011 | 1 | 2014 | 1 | 2015 | 5 | 2017 | 1 | 2018 | 1 | 2019 | 1 | 2020 | 2 |
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text, click here.
This graph shows the number and percent of publications by field.
Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications.
Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written.
To see the data as text, click here.
newest
oldest
line numbers
double spacing
all authors
publication IDs
|
Derived automatically from this person's publications.
_
People in Profiles who have published with this person.
_
People who share similar concepts with this person.
_
Search Department
_
|